Search
for
Sort by
Research 31–60 of 584
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
- Janus Kinase inhibitors in dermatology: a review
- Pharmacological Treatment of Alopecia
- 0975 Single-cell transcriptomic profiling reveals distinct immunopathogenic programs in alopecia totalis/universalis compared to patchy alopecia areata
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- Elevation of circulating DNAs of disease-associated cytokines in serum cell-free DNA from patients with alopecia areata
- P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- IN-SILICO STUDY OF BIOACTIVE COMPOUNDS OF NATURAL MATERIALS AS A JAK- SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION INHIBITOR FOR ANTI-ALOPECIA
- Myeloproliferative disorder associated with alopecia universalis
- Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Spotlight in Plastic Surgery: October 2022
- Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Emerging role of baricitinib in dermatology practice: All we need to know!
- Personalized Medicine in the Field of Inflammatory Skin Disorders
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
- Studi Molecular Docking Aktivitas Anti Alopecia pada Senyawa yang Terkandung dalam Daun Dadap Serep (Erythrina subumbrans (Hassk.) Merrill)
- Alopecia Areata: Current Review
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- Baricitinib Induced Hypoglycemic Seizures in a Patient with Hair Loss and Type I Diabetes Mellitus: A Case Report
- 42752 Evaluation of Eyebrow and Eyelash Regrowth and Patient Satisfaction in the Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata